Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
基本信息
- 批准号:9490464
- 负责人:
- 金额:$ 799.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functional
and integrated clinical and translational (C&T) research infrastructure that has raised the quality
and scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry,
the nation’s oldest historically black academic health science institution. VICTR will contribute to
the mission of the CTSA program while leveraging unique resources and expertise within
VICTR’s Hub with these aims: 1) Leverage VICTR’s strong collaborative energy to enhance
team science methodologies that propel transdisciplinary research approaches, and integrate
proven community engagement principles to stakeholders for all stages of research; 2) Develop,
implement and disseminate informatics and data organization methods to promulgate research
efficiency, quality, and preparedness and integrate data collection in the conduct of pragmatic
trials; 3) Ensure the translational science workforce is diverse and has the skills, knowledge,
and resources necessary to advance translation of discoveries; 4) Measurably improve the
efficiency, quality, and representativeness of C&T studies by enhancing and systematically
integrating services and programs that support highest quality research initiation and conduct;
5) Measurably improve the efficiency and quality of multi-site clinical trials, in collaboration with
the TICs and RICs, by leveraging centralized regulatory and legal agreements, providing rapid
feasibility and recruitment methods and practices, and creating and disseminating novel clinical
trial designs and methodologies; and 6) Utilize unique strengths leveraging novel resources
BioVU and PheWAS to guide drug development and repurposing.
范德比尔特临床和转化研究所(VICTR)是一个高度功能的
以及综合临床和转化(C&T)研究基础设施,提高了质量
以及在范德比尔特(Vanderbilt)和长期合作伙伴梅哈里(Meharry)进行的研究的科学严谨性,
该国历史上最古老的黑人学术健康科学机构。 Victr将为
CTSA计划的任务同时利用独特的资源和专业知识
Victr的枢纽以这些目的:1)利用Victr的强大协作能量来增强
推动跨学科研究方法并整合的团队科学方法
验证的社区参与原则向利益相关者的所有研究阶段; 2)发展,
实施并传播信息和数据组织方法来颁布研究
务实的效率,质量和准备和综合数据收集
试验; 3)确保转化科学劳动力是潜水员,并具有技能,知识,
以及推进发现翻译所需的资源; 4)测量改善
C&T研究的效率,质量和代表性,通过增强和系统地增强
集成支持最高质量研究计划和行为的服务和计划;
5)与与之合作的测量提高多站点临床试验的效率和质量
通过利用集中的监管和法律协议,抽动和RICS提供了快速
可行性和招聘方法和实践,并创建和传播新型临床
试用设计和方法; 6)利用独特的优势利用新的资源
Biovu和Phewas指导药物开发和重新利用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Gordon R Bernard的其他基金
ComPASS Collective for Community Engagement (C3E)
ComPASS 社区参与集体 (C3E)
- 批准号:1090337010903370
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Engaging Cooperative Sites for Trial Acceleration, Trust, Innovation, and Capability (ECSTATIC)
与试验加速、信任、创新和能力合作站点合作 (ECSTATIC)
- 批准号:1065068210650682
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE)
协调 ARDS、肺炎和败血症支持培训、组织和网络效率 (CAPSTONE)
- 批准号:1064745510647455
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:1039879910398799
- 财政年份:2021
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:1008458310084583
- 财政年份:2021
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:1060904910609049
- 财政年份:2021
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasma
范德比尔特临床和转化研究所 (VICTR) - 识别 SARS-CoV-2 恢复期血浆中功能免疫的相关性
- 批准号:1025456510254565
- 财政年份:2020
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
- 批准号:1017000910170009
- 财政年份:2020
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
- 批准号:94145179414517
- 财政年份:2017
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Passive Immunity Trial for Our Neighbors (PassITON): A randomized, placebo-controlled multi-site trial of anti-SARS-CoV-2 convalescent plasma to treat hospitalized adults with COVID-19
为我们的邻居进行的被动免疫试验 (PassITON):一项随机、安慰剂对照的多中心抗 SARS-CoV-2 恢复期血浆试验,用于治疗患有 COVID-19 的住院成人
- 批准号:1021894910218949
- 财政年份:2017
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
相似国自然基金
面向重大需求,优化科学基金资助临床研究的战略调研
- 批准号:82342004
- 批准年份:2023
- 资助金额:10 万元
- 项目类别:专项基金项目
基于实施科学视角的中医临床实践指南实施与评价研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于实施科学视角的中医临床实践指南实施与评价研究
- 批准号:72204061
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
科学基金支持临床医学研究的战略调研
- 批准号:
- 批准年份:2019
- 资助金额:25 万元
- 项目类别:专项基金项目
基于VEGFR1/PDGFR信号通路的黄芪、莪术配伍促肿瘤新生血管正常化的机制研究
- 批准号:81503270
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Renewal of The Mid-America CTSA Consortium (MACC) as a Regional Clinical Center for SIREN
更新中美洲 CTSA 联盟 (MACC) 作为 SIREN 的区域临床中心
- 批准号:1055044610550446
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
UNderstanding the Delivery of Low-Value CAre To CHildren and the Barriers to De-Implementation (UN-LATCH)
了解向儿童提供低价值护理以及取消实施的障碍 (UN-LATCH)
- 批准号:1064981110649811
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub
墨西哥湾沿岸联盟 (GCC) 研究评估和商业化中心
- 批准号:1078341410783414
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
Providers and Older Pain Patients with Prescription Opioid Dependence: A Qualitative Study to Understand Barriers to Opioid Taper, Cessation, and Transition to Buprenorphine.
具有处方阿片类药物依赖性的提供者和老年疼痛患者:一项定性研究,旨在了解阿片类药物逐渐减少、戒断和过渡到丁丙诺啡的障碍。
- 批准号:1067135810671358
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别:
UEM Collaborative Research Ethics Education Program
UEM 合作研究伦理教育计划
- 批准号:1075552310755523
- 财政年份:2023
- 资助金额:$ 799.21万$ 799.21万
- 项目类别: